Lupus Therapeutics to Test Potential Treatment for Lupus in Takeda Collaboration

New York, NY– March 1.  The Lupus Research Alliance and clinical affiliate, Lupus Therapeutics will partner with Takeda Pharmaceutical Company Limited to evaluate the investigational biologic TAK-079 as a potential new therapy for lupus in a Phase 1 trial (NCT03724916).  TAK-079 is a fully human monoclonal antibody, meaning that it is produced in the laboratory using human […] Read More